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Abstract 
Background: Chronic drug abuse and sexual dysfunction specifically erectile dysfunction may lead drug 
abusers to seek over-the-counter or non-prescription medications, out of which Sildenafil citrate, sold as the 
trade name of Viagra® can be considered as a prime and important treatment. Therefore, the research 
purpose was to draw a comparison and review the role of methamphetamine abuse and sildenafil use in 
increasing the likelihood of high-risk sexual behaviors (both concomitant and non-concomitant use). 
Methods: Hence, a total of 40 patients diagnosed with methamphetamine abuse were recruited through the 
administration of structured clinical interview for DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition), through purposive sampling and subsequent to being qualified in accordance with 
the selection criteria by psychologists and general practitioners. All the 40 drug abusers  
(20 methamphetamine abusers with concomitant use of Aphrodisiac drugs (sexual stimulant pills) and 20 
methamphetamine abusers) described their sexual risk behaviors subsequent to the drug use. 
Findings: Supported the between-group difference that is to say that, the group with concomitant 
methamphetamine abuse differed significantly in all the items when compared with the control group. 
However, this group scored lower on the item of sexual intercourse with drug addicted prostitutes using 
condom and both groups demonstrated high pick on this item. 
Conclusion: Overall, the concomitant methamphetamine chronic abuse with sexual stimulant drugs 
generates Aphrodisiac drugs impulses and is found to be related to higher frequencies of sexual risk 
behaviors and sexual intercourse with addicted prostitutes. 
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Introduction 
Methamphetamine (methylamphetamie) can be 
classified into the drug class of central nervous 
system stimulants and is a psychostimulant and 
psychoactive drug with numerous slang terms 
that vary from region to region such as ice, clouds 
crystal or glass.1,2 Methamphetamine triggers a 
cascading release of dopamine in the brain 
mechanism, and its psychological effects can be 
marked by dramatic mood swings from euphoria 
and elation to irritability.3,4 
Methamphetamine is most structurally similar 
to amphetamine and most commonly, it is found 
as a colorless, bitter and non-smelling crystalline 
solid. Long-term use can have irritability, 
psychomotor agitation, increased risk of 
Parkinson’s disease, chronic depression and 
sexual impulsiveness.5,6 In addition, delusions of 
grandiosity, hallucinations, hyperactivity, 
excessive feelings of power and invincibility, 
repetitive and obsessive behaviors, paranoia are 
some of the physical and psychological symptoms 
of methamphetamine abuse with chronic use 
and/or high dose.7 At the start of amphetamine 
abuse, the abuser may exhibit exaggerated and 
changing sexual attitude and feelings, 
unprotected and unsafe sex acts, strong and 
uncontrollable sexual impulses, frequent change 
of sexual partners and irresponsible sexual 
behavior.8 The abuser is not able to perceive 
wrong-right behaviors while having sex and may 
display impulsive or reckless behavior. Over time, 
substance abuse and dysfunction in sexual 
performance specifically erectile dysfunction may 
give rise to the use of illegal aphrodisiac drugs 
(sexual stimulant pills). Overall, 
methamphetamine use is found to be related to 
higher frequencies of high-risk sexual activities.9,10 
Sildenafil citrate, sold as Viagra®, revatio and 
under various other trade names, is a drug used 
to treat erectile dysfunction and pulmonary 
arterial hypertension. It acts by inhibiting cylic 
guanosine monophosphate (cGMP)-specific 
phosphodiesterase Type 5, an enzyme that 
promotes degradation of cGMP, which regulates 
blood flow in the penis. Since becoming available 
in 1998, sildenafil has been the prime treatment 
for erectile dysfunction.11 Patterson and Semple,12 
Crosby and Mettey,13 Halkitis and Green,14 and 
Spindler et al.2 found that illegal and even legal 
stimulant drugs in substance abusers, allows for 
further probability of sexual risk behaviors. This 
negative combined synergistic effect is called  
sex-drug cocktail in the west. Methamphetamines 
entail higher risk of shaping and reinforcing sexual 
risk behaviors when compared to other substances 
such as hashish, opium, crack, heroin, Ritalin and 
cocaine. This seems to be due to the neurochemical 
synergistic reaction. One out of five HIV (human 
immunodeficiency virus)-positive participants was 
methamphetamine abuser in a longitudinal study 
done in Los Angeles.15 
The research findings indicate that 
methamphetamine abuse heighten the risk of 
engagement in unprotected intercourse and riskier 
sexual behaviors.16 The present research is an 
attempt to shed light on the role of 
methamphetamine abuse and sildenafil (Viagra®) 
use in increasing the likelihood of high-risk sexual 
behaviors (concomitant and non-concomitant use). 
Methods 
A total of 40 patients diagnosed with 
methamphetamine abuse were recruited through 
the administration of structured clinical interview 
for DSM-IV (SCID-I). The diagnosed abusers were 
selected through purposive sampling.17,18 
methamphetamine abusers with concomitant and 
non-concomitant use of aphrodisiac drugs (sexual 
stimulant pills) were selected from among the 
patients who were referred to counseling and 
harm reduction centers (triangular counseling 
clinics of AIDS (acquired immune deficiency 
syndrome), substance abuse and sexually 
transmitted diseases treatment) in Tehran, Iran. 
Subsequent to being qualified in accordance with 
selection criteria by psychologists and general 
practitioners, all the 40 drug abusers  
(20 methamphetamine abusers with concomitant 
use of aphrodisiac drugs (sexual stimulant pills) 
and 20 methamphetamine abusers) described their 
sexual risk behaviors subsequent to the drug use. 
The inclusion criteria included chronic 
methamphetamine abuse (over 3.5 years) at the 
present time, lack of multiple substance abuse 
during the previous addiction or earlier (the main 
previous addiction had started with 
methamphetamine), aged between 25 and 40 
years and the minimum level of secondary 
education to fill out the required forms and 
checklists. The exclusion criteria were having an 
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acute physical illness and concurrent use of other 
specific substances before or during the study. 
To achieve this goal, The SCID-I Axis 1 
disorders, was conducted by a clinical 
psychologist. Subsequent to the initial diagnosis 
of chronic methamphetamine abuse, the above 
criteria were considered to select the eligible 
representative sample (Table 1). Comorbidity 
with other disorders is usually observed among 
the patients with substance abuse.19 Ladouceur  
et al.20 have noticed the same problem in their 
clinical studies. According to this approach and in 
order to overcome this problem we have selected 
individuals with the primary diagnosis of chronic 
methamphetamine addiction and concomitant 
sexual abuse drugs. Therefore, 40 controlled 
patients were enrolled subsequent to the selection 
of the eligible sample. 
SCID-Clinical version (CV): The SCID-I Axis 1 
disorders: SCID-CV, which was developed by 
Spitzer21 was specially designed as an adaptation 
of the SCID that is intended to introduce the 
benefits of structured interviewing into clinical 
and research setting. SCID-CV helps not to resort 
to the lengthier and more complex process used 
principally in research studies and dispose of 
other diagnostic categories which are not related 
to the study.22 The SCID-CV is divided into six 
self-contained modules covering: module A: 
mood episode, module B: psychotic symptoms, 
module C: psychotic disorders, module D: mood 
disorders, module E: substance use disorders, 
module F: anxiety and other disorder, also 
included in module F are disorders without 
diagnostic criteria such as agoraphobia, social 
phobia, specific phobia, etc. The SCID-CV may be 
administered to either psychiatric or general 
medical patients. It is most appropriate for adults 
(18 years and over), but with slight modification, 
may be used with adolescents.23 
This instrument can't be carried out with 
patients who suffer from serious cognitive 
disorders or exhibit severe and distressing 
symptoms of psychotic disorders and having  
acquired at least 8 years of education is required 
for full understanding.24 Tran and Haaga25 have 
reported the results indicate moderate to good 
reliability among formulations constructed by 
teams of independent clinician that was equal to 
0.60 based on a weighted kappa. A Persian 
version of this interview was administered on 229 
individuals by Sharifi et al.26 and the result of the 
kappa coefficient was over 0.60. In order to assess 
the validity of the instrument, Bakhtiyari22 asked a 
panel of judges formally to rate the validity, 
which was rated as having satisfactory and 
acceptable validity to be used in clinical setting. 
The test was also shown to have a high 1-week 
test–retest reliability (r = 0.95). 
Substance Abusers’ sexual behaviors 
questionnaire: this 12-item questionnaire was 
designed and developed by Vaziri and Lotfi 
Kashani27 and measures sexual desire and 
performance, peak sexual demands and sexual 
risk behaviors. Each dimension is covered with 4 
questions. This questionnaire was administered 
on 30 substance abusers and its test-retest 
reliability with 15 days of the time interval was 
equal to 0.76. Each question has been designed in 
a way to provide a total score for each dimension, 
and it is possible to compare individuals in each 
of the possible responses. This questionnaire is 
based on a four-point scale ranging from 0 
“never” to 3 “always” and can be marked verbally 
or in written form.24 With regard to the research 
condition and patients’ chronic problem and 
subsequent to the required evaluations, the short 
5-item questionnaire was designed and completed 
by the respondents (Table 1). 
Results 
As seen, the sample population was selected 
based on the demographic characteristics and 
comparable clinical severity in terms of age, sex 
and duration of abuse. The mean age and the 
mean of the total score of the first group with 
methamphetamine abuse and taking sexual 
stimulant drug were 34.50 and 2.24, respectively.
 
Table 1. The aim of questionnaires’ administration and their timing 
Questionnaire Aim Timing 
SCID-I Clinical differential diagnosis of methamphetamine abuse Prior to patient selection and during the 
screening phase 
Oral interview Self-report diagnosis of methamphetamine abuse outlining the baseline level 
SCID-I: Structured clinical interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition ) 
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Moreover, the mean age and the mean of the 
total score of the second group with 
methamphetamine abuse were 35.00 and 0.97, 
respectively (Table 2). 
Table 3 illustrates the means of the items in 
the questionnaire in two groups. As observed, 
the first group with concomitant abuse of 
methamphetamine and sexual stimulant drug 
scored higher on the items of sexual power and 
performance with substance abuse, rapid, sharp 
and frequent increase of sexual behavior, sexual 
intercourse with strangers without condom, anal 
and oral sex and masturbation and sexual 
intercourse with drug addicted prostitutes  
with condom. 
Moreover, the group with concomitant abuse 
of methamphetamine and sexual stimulant drug 
scored higher on the items of sexual power and 
performance with substance abuse, rapid, sharp 
and frequent increase of sexual behavior, sexual 
intercourse with strangers without condom, anal 
and oral sex and masturbation and sexual 
intercourse with drug addicted prostitutes with 
condom (Table 3). 
Discussion 
The data presented in figure two demonstrate the 
between-group difference on all the items 
specifically the fourth one. Aphrodisiac drugs 
(sexual stimulant pills) users showed a sharp 
increase of sexual stimulations on all the items 
when compared with the non-using group. 
Overall, as observed, both groups showed 
tendency to have sexual intercourse with drug 
addicted prostitutes using condoms. 
The sexual desire in single methamphetamine  
drug abuse was only slightly less than concomitant 
methamphetamine abuse and Aphrodisiac drugs 
(sexual stimulant pills). However, high-risk sexual 
behaviors are due to their decreasing and 
unacceptable level of socio-sexual networks, 
financial poverty, and emotional strains. 
Unpleasant and visible symptoms of 
methamphetamine addicted individuals result in 
the elimination of their names from the customers’ 
list of healthier and more high-class prostitutes. 
Therefore, they seek for street and low-cost 
prostitutes who are typically addicted. 
Concomitant methamphetamine abuse with sexual 
stimulant drugs generates sexual impulses that 
reinforce high-risk sexual behaviors with a 
network of sexual partners who are likely of 
contracting a sexually transmitted infection (STI) 
even with using a condom. Providing and 
distributing condoms can help these individuals 
recognize the benefits of the less riskier sexual 
activities and reduced likelihood of contracting 
HIV and STI; however, some of them cannot 
control themselves in sexual intercourse with 
partners who are highly likely of being HIV- or 
STI-positive and their preference was obvious on 
the 5th item of the questionnaire which indicated 
their tendency in using condom in high-risk sexual 
activities (Figure 1). 
Conclusion 
Overall, it can be concluded that the concomitant 
methamphetamine chronic abuse with Aphrodisiac 
drugs (sexual stimulant pills) generates  
aphrodisiac drugs impulses and is found to be 
related to higher frequencies of sexual risk 
behaviors and sexual intercourse with addicted
 
Table 2. Patients’ demographic characteristics 
Age range (year) Sex No. Duration Sample Mean of total score 
34.5 Male 20 4 years, approximately Methamphetamine abuse and 
sexual stimulant drugs 2.24 
35.0 Male 20 4 years, approximately Methamphetamine abuse 0.97 
 
Table 3. Comparisons of groups’ mean scores on the five items of substance abusers’ sexual behaviors 
questionnaire 
Item Mean Concomitant abuse Non-concomitant abuse 
Increase of sexual power and performance with substance abuse 2.30 0.73 
Rapid, sharp and frequent increase of sexual behavior 2.40 0.83 
Sexual intercourse with strangers without condom 1.90 0.90 
Anal and oral sex and masturbation 1.80 0.70 
Sexual intercourse with drug addicted prostitutes with condom 2.80 1.70 
Synergistic Effect of Combined Methamphetamine with Aphrodisiac Drugs Hosseinifard et al. 
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Figure 1. Comparison of high-risk sexual behaviors in two groups of non-concomitant methamphetamine abuse 
and concomitant methamphetamine abuse and sexual stimulant drugs 
 
prostitutes. These findings point to sexual 
marathons as a possible contributor to rising HIV 
rates in the combined methamphetamine drug and 
sexual stimulant drugs. 
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